A	B	C	D	E	F	G	H
1	Main
2		Brand	Generic	Indication	Approved	Economics	MOA
3		Tamiflu	oseltamivir	Influenza	1999	Gilead	Neuraminidase
4		Valcyte	valganciclovir	Herpes	3/9/2001
5
6		Dalcetrapib fails.
7		July 2013: aleglitazar stopped
8		2014: bitopertin (RG1678) fails.
9
10
11
12		7166, triple reuptake inhibitor for depression, abandoned.
13		7351, TAAR1 partial agonist for depression, abandoned
14		R1579 (carmegliptin)	T2D	II	1	DPP-IV		NCE
15		R667 (palovarotene)	Emphysema	II	1	Nuclear Receptor Agonist		NCE
16		RG3487	Alzheimer's, Schizophrenia	II	1	Alpha-7		NCE
17		RG3484	Cervical Neoplasia	II	1	HPV16 vaccine		Vaccine
18		R7128	HCV	II	VRUS	Nucleoside Polymerase	ANDS, VX-222	NCE
19		R7227	HCV	I	ITMN	Protease Inhibitor	11/09: Safety issue	NCE
20		R7234	T2D	I	1	11-beta-HSD		NCE
21		R4929	T2D	I	1	11-beta-HSD		NCE
22		R7089	T2D	I	1	Y2R peptide agonist		NCE
23		RG7426	T1D	I	1			NCE
24		RO4998452	T2D	II	1			NCE
25		EVT101	Treatment Resistant Depression	II	1	NMDA?		NCE?
26		RG7090 (basimglurant)	Depression	II	1	mGluR5	Outlicensed to Noema Pharma	NCE
27		R7201 (tofogliflozin)	T2D	II	Chugai	SGLT2	NCE
28		RG7423	Solid Tumors	II	1	Small Molecule	NCE
29		R3637 (lebrikizumab)	Asthma	II	LLY	Anti IL-13	Antibody
30		RG3638 (onartuzumab)	Solid Tumors	III	1	MetMab	Antibody
31		RG3639 (dulanermin)	Solid Tumors	II	AMGN	DR5?	Protein
32		R7376 (PLX5568)	Polycystic Kidney Disease	II	Plexxicon	RAF kinase inhibitor	NCE
33		R1512	PVD	I	Genmab	Selectin	Antibody
34		ABT-263 (navitoclax) RG7601?	R/R CLL	II	ABT	Bcl-2	NCE
35		R7417 (lampalizumab)	AMD	I	1	Anti-Factor-D	NCE
36		R7273	Dyslipidemia	I	1	ABCA1 inducer	NCE